Imad Ghanem Qasim
Imad Ghanem Qasim has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Abdalfattah Sharad
Madenat Alelem University College
1 shared publication - Hastyar Hamarashid Najmuldeen
Department of Medical Laboratory Analysis, College of Health Sciences, Cihan University Sulaimaniya, Sulaymaniyah City, Kurdistan, Iraq
1 shared publication - Murzaeva Mariia1 shared publication
- Nazarzoda Khusin Nazir
Avicenna Tajik State Medical University
1 shared publication - Nurila Aryntayeva
Department of Clinical Disciplines, Al-Farabi Kazakh National University, Almaty 050040, Kazakhstan
1 shared publication - Pirmatova Alina1 shared publication
Latest Publications
- Open Access
- 14 November 2025
- Published by UK Scientific Publishing Limited in Trends in Immunotherapy
- p. 160-173
Bacterial Community Diversity, Richness, and Possible Immunotherapies Association in Response to Spray-Dried Porcine Plasma-Fed Diet: An Animal Model
This study aims to demonstrate the significance of employing non-invasive dietary intervention to control the diversity and abundance of bacterial communities in feces. The indexing databases Scopus, PubMed/Medline, ISI Web of Science, Embase, Cochrane Central, and CINAHL were extensively searched. Only 13 of 541 papers found in the initial searches met the criteria. Seven studies involving 210 animals were included in this meta-analysis. The SDPP group showed statistically lower Shannon (SMD: 1.20, 95% CI: 0.22–2.19, I2: 88%, p = 0.02) and Chao1 (SMD: 2.95, 95% CI: 1.99–3.91, I2: 77%, p < 0.00001) indices than the control group. The SDPP-diet fed group showed notably lower OTU counts compared to the control group (SMD: 2.99, 95% CI: 0.67–5.32, I2: 97%, p = 0.01). The Firmicutes/Bacteroidetes ratio is reliably increased following the SDPP-fed diet (SMD: 0.68, 95% CI: 0.13–1.23, I2: 0%, p = 0.02). While noticeable differences existed between studies and difficulties were encountered in replicating basic ecological measurements, the purpose of this analysis was to identify the consistent characteristics of the gut microbiota's response to the SDPP diet, thereby pinpointing specific areas for further mechanistic research.
- 14 November 2025
- Published by UK Scientific Publishing Limited in Trends in Immunotherapy
- p. 160-173
Open AccessBacterial Community Diversity, Richness, and Possible Immunotherapies Association in Response to Spray-Dried Porcine Plasma-Fed Diet: An Animal Model
This study aims to demonstrate the significance of employing non-invasive dietary intervention to control the diversity and abundance of bacterial communities in feces. The indexing databases Scopus, PubMed/Medline, ISI Web of Science, Embase, Cochrane Central, and CINAHL were extensively searched. Only 13 of 541 papers found in the initial searches met the criteria. Seven studies involving 210 animals were included in this meta-analysis. The SDPP group showed statistically lower Shannon (SMD: 1.20, 95% CI: 0.22–2.19, I2: 88%, p = 0.02) and Chao1 (SMD: 2.95, 95% CI: 1.99–3.91, I2: 77%, p < 0.00001) indices than the control group. The SDPP-diet fed group showed notably lower OTU counts compared to the control group (SMD: 2.99, 95% CI: 0.67–5.32, I2: 97%, p = 0.01). The Firmicutes/Bacteroidetes ratio is reliably increased following the SDPP-fed diet (SMD: 0.68, 95% CI: 0.13–1.23, I2: 0%, p = 0.02). While noticeable differences existed between studies and difficulties were encountered in replicating basic ecological measurements, the purpose of this analysis was to identify the consistent characteristics of the gut microbiota's response to the SDPP diet, thereby pinpointing specific areas for further mechanistic research.
- Open Access
- 30 October 2025
- Published by UK Scientific Publishing Limited in Trends in Immunotherapy
- p. 73-85
Glycoprotein G-Based Vaccines for Nipah Virus: Epidemiology, Molecular Insights, Benefits, and Limitations
Nipah virus (NiV) is a highly virulent zoonotic pathogen associated with significant mortality rates and limited treatment options, posing a significant public health threat. This review explores the epidemiology, molecular structure, and vaccine development efforts targeting glycoprotein G, a critical component of the virus's entry mechanism. Advances in structural biology and immunogenetics have highlighted the potential of glycoprotein G-based vaccines in preventing NiV infections. Despite promising preclinical results, challenges such as immune evasion, safety concerns, and limited clinical trials persist. Additionally, we examine the benefits of glycoprotein G-based vaccines in enhancing immune responses and preventing viral entry, as well as the limitations posed by genetic diversity and cross-reactivity. This review highlights the critical need for ongoing research to overcome existing challenges and guide future vaccine development efforts against NiV. It further underscores the necessity of innovative approaches in vaccine design to reduce the global burden of NiV infections. Glycoprotein G-based vaccines represent a promising avenue for combating NiV infections. Advances in structural biology, immune system targeting, and delivery system technology are paving the way for more effective vaccines. However, overcoming challenges such as cross-reactivity and safety concerns will require continued innovation and collaboration.
- 30 October 2025
- Published by UK Scientific Publishing Limited in Trends in Immunotherapy
- p. 73-85
Open AccessGlycoprotein G-Based Vaccines for Nipah Virus: Epidemiology, Molecular Insights, Benefits, and Limitations
Nipah virus (NiV) is a highly virulent zoonotic pathogen associated with significant mortality rates and limited treatment options, posing a significant public health threat. This review explores the epidemiology, molecular structure, and vaccine development efforts targeting glycoprotein G, a critical component of the virus's entry mechanism. Advances in structural biology and immunogenetics have highlighted the potential of glycoprotein G-based vaccines in preventing NiV infections. Despite promising preclinical results, challenges such as immune evasion, safety concerns, and limited clinical trials persist. Additionally, we examine the benefits of glycoprotein G-based vaccines in enhancing immune responses and preventing viral entry, as well as the limitations posed by genetic diversity and cross-reactivity. This review highlights the critical need for ongoing research to overcome existing challenges and guide future vaccine development efforts against NiV. It further underscores the necessity of innovative approaches in vaccine design to reduce the global burden of NiV infections. Glycoprotein G-based vaccines represent a promising avenue for combating NiV infections. Advances in structural biology, immune system targeting, and delivery system technology are paving the way for more effective vaccines. However, overcoming challenges such as cross-reactivity and safety concerns will require continued innovation and collaboration.